These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

388 related articles for article (PubMed ID: 31004028)

  • 1. Venetoclax resistance and acquired
    Tausch E; Close W; Dolnik A; Bloehdorn J; Chyla B; Bullinger L; Döhner H; Mertens D; Stilgenbauer S
    Haematologica; 2019 Sep; 104(9):e434-e437. PubMed ID: 31004028
    [No Abstract]   [Full Text] [Related]  

  • 2. Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia.
    Blombery P; Anderson MA; Gong JN; Thijssen R; Birkinshaw RW; Thompson ER; Teh CE; Nguyen T; Xu Z; Flensburg C; Lew TE; Majewski IJ; Gray DHD; Westerman DA; Tam CS; Seymour JF; Czabotar PE; Huang DCS; Roberts AW
    Cancer Discov; 2019 Mar; 9(3):342-353. PubMed ID: 30514704
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiple BCL2 mutations cooccurring with Gly101Val emerge in chronic lymphocytic leukemia progression on venetoclax.
    Blombery P; Thompson ER; Nguyen T; Birkinshaw RW; Gong JN; Chen X; McBean M; Thijssen R; Conway T; Anderson MA; Seymour JF; Westerman DA; Czabotar PE; Huang DCS; Roberts AW
    Blood; 2020 Mar; 135(10):773-777. PubMed ID: 31951646
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Landscape of
    Kotmayer L; László T; Mikala G; Kiss R; Lévay L; Hegyi LL; Gróf S; Nagy T; Barna G; Farkas P; Weisinger J; Nagy Z; Balogh A; Masszi T; Demeter J; Sulák A; Kohl Z; Alizadeh H; Egyed M; Pettendi P; Gergely L; Plander M; Pauker Z; Masszi A; Matolcsy A; Szász R; Bödör C; Alpár D
    Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982875
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel BCL2 mutations in venetoclax-resistant, ibrutinib-resistant CLL patients with BTK/PLCG2 mutations.
    Lucas F; Larkin K; Gregory CT; Orwick S; Doong TJ; Lozanski A; Lozanski G; Misra S; Ngankeu A; Ozer HG; Sampath D; Thangavadivel S; Yilmaz SA; Rogers KA; Byrd JC; Woyach JA; Blachly JS
    Blood; 2020 Jun; 135(24):2192-2195. PubMed ID: 32232486
    [No Abstract]   [Full Text] [Related]  

  • 6. Potential of BCL2 as a target for chronic lymphocytic leukemia treatment.
    Moia R; Diop F; Favini C; Kodipad AA; Gaidano G
    Expert Rev Hematol; 2018 May; 11(5):391-402. PubMed ID: 29561706
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structures of BCL-2 in complex with venetoclax reveal the molecular basis of resistance mutations.
    Birkinshaw RW; Gong JN; Luo CS; Lio D; White CA; Anderson MA; Blombery P; Lessene G; Majewski IJ; Thijssen R; Roberts AW; Huang DCS; Colman PM; Czabotar PE
    Nat Commun; 2019 Jun; 10(1):2385. PubMed ID: 31160589
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of recurrent genomic alterations in the apoptotic machinery in chronic lymphocytic leukemia patients treated with venetoclax monotherapy.
    Popovic R; Dunbar F; Lu C; Robinson K; Quarless D; Warder SE; Mukherjee N; Pesko J; Souers AJ; Waring JF; Davids MS; Tausch E; Stilgenbauer S; Ross JA; Leverson JD; Kim SY; Chyla BJ
    Am J Hematol; 2022 Feb; 97(2):E47-E51. PubMed ID: 34779028
    [No Abstract]   [Full Text] [Related]  

  • 9. Expression of BCL2 alternative proteins and association with outcome in CLL patients treated with venetoclax.
    Marques-Piubelli ML; Schlette EJ; Khoury JD; Furqan F; Vega F; Soto LMS; Wistuba II; Wierda WG; Konopleva M; Ferrajoli A; Strati P
    Leuk Lymphoma; 2021 May; 62(5):1129-1135. PubMed ID: 33327833
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genomics of Resistance to Targeted Therapies.
    Thangavadivel S; Woyach JA
    Hematol Oncol Clin North Am; 2021 Aug; 35(4):715-724. PubMed ID: 34174982
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resistance to ABT-199 induced by microenvironmental signals in chronic lymphocytic leukemia can be counteracted by CD20 antibodies or kinase inhibitors.
    Thijssen R; Slinger E; Weller K; Geest CR; Beaumont T; van Oers MH; Kater AP; Eldering E
    Haematologica; 2015 Aug; 100(8):e302-6. PubMed ID: 25957396
    [No Abstract]   [Full Text] [Related]  

  • 12. Venetoclax: Bcl-2 inhibition for the treatment of chronic lymphocytic leukemia.
    Del Poeta G; Postorino M; Pupo L; Del Principe MI; Dal Bo M; Bittolo T; Buccisano F; Mariotti B; Iannella E; Maurillo L; Venditti A; Gattei V; de Fabritiis P; Cantonetti M; Amadori S
    Drugs Today (Barc); 2016 Apr; 52(4):249-60. PubMed ID: 27252989
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Splicing modulation sensitizes chronic lymphocytic leukemia cells to venetoclax by remodeling mitochondrial apoptotic dependencies.
    Ten Hacken E; Valentin R; Regis FFD; Sun J; Yin S; Werner L; Deng J; Gruber M; Wong J; Zheng M; Gill AL; Seiler M; Smith P; Thomas M; Buonamici S; Ghia EM; Kim E; Rassenti LZ; Burger JA; Kipps TJ; Meyerson ML; Bachireddy P; Wang L; Reed R; Neuberg D; Carrasco RD; Brooks AN; Letai A; Davids MS; Wu CJ
    JCI Insight; 2018 Oct; 3(19):. PubMed ID: 30282833
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Venetoclax in Patients with Previously Treated Chronic Lymphocytic Leukemia.
    Roberts AW; Stilgenbauer S; Seymour JF; Huang DCS
    Clin Cancer Res; 2017 Aug; 23(16):4527-4533. PubMed ID: 28100580
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study.
    Stilgenbauer S; Eichhorst B; Schetelig J; Coutre S; Seymour JF; Munir T; Puvvada SD; Wendtner CM; Roberts AW; Jurczak W; Mulligan SP; Böttcher S; Mobasher M; Zhu M; Desai M; Chyla B; Verdugo M; Enschede SH; Cerri E; Humerickhouse R; Gordon G; Hallek M; Wierda WG
    Lancet Oncol; 2016 Jun; 17(6):768-778. PubMed ID: 27178240
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SOHO State of the Art Updates and Next Questions | Mechanisms of Resistance to BCL2 Inhibitor Therapy in Chronic Lymphocytic Leukemia and Potential Future Therapeutic Directions.
    Bennett R; Thompson E; Tam C
    Clin Lymphoma Myeloma Leuk; 2022 Nov; 22(11):795-804. PubMed ID: 35970756
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinicopathological features and outcomes of progression of CLL on the BCL2 inhibitor venetoclax.
    Anderson MA; Tam C; Lew TE; Juneja S; Juneja M; Westerman D; Wall M; Lade S; Gorelik A; Huang DCS; Seymour JF; Roberts AW
    Blood; 2017 Jun; 129(25):3362-3370. PubMed ID: 28473407
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Venetoclax for the Treatment of Chronic Lymphocytic Leukemia.
    Eradat H
    Curr Hematol Malig Rep; 2019 Oct; 14(5):469-476. PubMed ID: 31512151
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States.
    Mato AR; Thompson M; Allan JN; Brander DM; Pagel JM; Ujjani CS; Hill BT; Lamanna N; Lansigan F; Jacobs R; Shadman M; Skarbnik AP; Pu JJ; Barr PM; Sehgal AR; Cheson BD; Zent CS; Tuncer HH; Schuster SJ; Pickens PV; Shah NN; Goy A; Winter AM; Garcia C; Kennard K; Isaac K; Dorsey C; Gashonia LM; Singavi AK; Roeker LE; Zelenetz A; Williams A; Howlett C; Weissbrot H; Ali N; Khajavian S; Sitlinger A; Tranchito E; Rhodes J; Felsenfeld J; Bailey N; Patel B; Burns TF; Yacur M; Malhotra M; Svoboda J; Furman RR; Nabhan C
    Haematologica; 2018 Sep; 103(9):1511-1517. PubMed ID: 29880613
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MicroRNA Dysregulation to Identify Novel Therapeutic Targets.
    Croce CM
    Curr Top Microbiol Immunol; 2017; 407():191-203. PubMed ID: 28653191
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.